论文信息 - Enhancing thrombolytic efficacy by means of "front-loaded" administration of tissue plasminogen activator. - 字舞流文

Enhancing thrombolytic efficacy by means of "front-loaded" administration of tissue plasminogen activator.

[1] U. Tebbe,et al. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. , 1989, Journal of the American College of Cardiology.

[2] E. Braunwald. Thrombolytic reperfusion of acute myocardial infarction: resolved and unresolved issues. , 1988, Journal of the American College of Cardiology.

[3] R. Califf,et al. Comparison of two dose regimens of intravenous tissue plasminogen activator for acute myocardial infarction. , 1988, The American journal of cardiology.

[4] D. Collen. Molecular mechanism of action of newer thrombolytic agents. , 1987, Journal of the American College of Cardiology.

[5] K. Lee,et al. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. , 1987, The New England journal of medicine.

[6] E. Topol,et al. A multicenter, randomized, placebo-controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (activase) in acute myocardial infarction. , 1987, Journal of the American College of Cardiology.

[7] W. Ganz,et al. The thrombolysis in myocardial infarction (TIMI) trial. , 1985, The New England journal of medicine.

[8] H. S. Mueller,et al. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.